
Zomedica Corp. ZOM
Annual report 2025
added 03-16-2026
Zomedica Corp. Total Current Liabilities 2011-2026 | ZOM
Annual Total Current Liabilities Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.45 M | 9.33 M | 9.03 M | 7.81 M | 4.34 M | 2.03 M | 2.09 M | 2.38 M | 829 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.45 M | 829 K | 5.25 M |
Total Current Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
3.81 M | - | 7.5 % | $ 6.35 M | ||
|
Assertio Holdings
ASRT
|
128 M | $ 18.41 | -1.02 % | $ 118 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | ||
|
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
27 M | - | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | ||
|
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | ||
|
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B | ||
|
Cumberland Pharmaceuticals
CPIX
|
31.6 M | $ 3.14 | 2.28 % | $ 44.1 M | ||
|
Jupiter Wellness
JUPW
|
5.98 M | - | - | $ 33.6 M | ||
|
Neoleukin Therapeutics
NLTX
|
16.4 M | - | - | $ 193 M | ||
|
Bausch Health Companies
BHC
|
4.3 B | $ 5.35 | 1.71 % | $ 1.95 B | ||
|
Canopy Growth Corporation
CGC
|
94.4 M | $ 1.04 | 4.83 % | $ 112 M | ||
|
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | ||
|
ProPhase Labs
PRPH
|
16.1 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | ||
|
Harrow Health
HROW
|
96.3 M | $ 36.73 | 3.67 % | $ 1.35 B | ||
|
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | ||
|
Evolus
EOLS
|
75.3 M | $ 4.09 | 0.25 % | $ 264 M | ||
|
Emergent BioSolutions
EBS
|
651 M | $ 8.39 | 6.88 % | $ 430 M | ||
|
Organogenesis Holdings
ORGO
|
77.5 M | $ 2.39 | 5.75 % | $ 315 M | ||
|
Pacira BioSciences
PCRX
|
310 M | $ 23.25 | 3.2 % | $ 1.08 B | ||
|
Relmada Therapeutics
RLMD
|
6.43 M | $ 7.01 | 3.85 % | $ 277 M | ||
|
SCYNEXIS
SCYX
|
5.73 M | $ 1.0 | 3.87 % | $ 49.9 M | ||
|
Solid Biosciences
SLDB
|
33.5 M | $ 8.02 | 3.62 % | $ 702 M | ||
|
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 2.29 | 3.62 % | $ 2.84 M | ||
|
Tilray
TLRY
|
433 M | $ 6.75 | 4.49 % | $ 4.17 B | ||
|
Veru
VERU
|
11.9 M | $ 2.55 | 2.82 % | $ 344 M | ||
|
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | ||
|
Viatris
VTRS
|
6.75 B | $ 13.57 | 3.12 % | $ 16.3 B | ||
|
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | ||
|
cbdMD
YCBD
|
8.62 M | $ 0.7 | -0.19 % | $ 3.02 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
9.58 M | $ 0.94 | -1.12 % | $ 33.8 M | ||
|
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
7.4 M | $ 0.62 | 1.57 % | $ 2.66 M | ||
|
TherapeuticsMD
TXMD
|
4.78 M | $ 2.05 | 1.49 % | $ 23.7 M |